

<b>Response to Notice to Comply Under 35 USC § 371</b>	Attorney Docket No.: <b>HOUSEEI.006NP</b>
	First Named Inventor: <b>Hung et al.</b>
	Int'l Application No.: <b>PCT/US03/06314</b>
	US Application No.: <b>10/506,414</b>
	Entered National Phase: <b>August 31, 2004</b>
Title: <b>HUMAN SCHWANNOMA CELL LINE</b>	
<b>Direct all correspondence to Customer No.: 20995</b>	
Date: April 15, 2005 Page 1 of 2	

**Mail Stop PCT**  
 United States Patent and Trademark Office  
 PO Box 1450  
 Alexandria, VA 22313-1450

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop: PCT, United States Patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450, on

April 15, 2005

(Date)

Marina L. Gorder, Reg. No. 52,950

Applicant herewith submits to the US Designated/Elected Office (DO/EO/US) the following items and other information:

- (X) This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
- (X) Copy of the Notification To Comply under 35 USC 371 dated February 16, 2005.
- (X) Request to Use Computer Readable Form From Another Application.
- (X) Return prepaid postcard.

**FILING FEES NOT YET PAID:**

FEE CALCULATION				
FEE TYPE		LARGE FEE	CALCULATION	TOTAL
Late Oath/Decl.	37 CFR § 1.492(h)	1617 (\$130)		\$0
Excess Claims	27 - 27 = 0	1615 (\$50)	0 x 50 =	\$0
Excess Ind. Claims	9 - 9 = 0	1614 (\$200)	0 x 200 =	\$0
Multiple Claim	37 CFR § 1.492(f)	1616 (\$360)		\$0
SUB TOTAL				\$0
The present application qualifies for Small Entity status under 37 CFR § 1.27. Fee reduced by 1/2.				(\$0)
Late English Trans	37 CFR § 1.492(i)	1618 (\$130)		\$0
TOTAL FEE DUE				\$0

**Response to Notice to  
Comply Under 35 USC § 371**


Attorney Docket No.: **HOUSEEL006NP**  
First Named Inventor: **Hung et al.**  
Int'l Application No.: **PCT/US03/06314**  
US Application No.: **10/506,414**  
Entered National-Phase: **August 31, 2004**  
Title: **HUMAN SCHWANNOMA CELL LINE**

**Direct all correspondence to Customer No.: 20995**

Date: April 15, 2005

Page 2 of 2

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 11-1410.



---

Marina L. Gonsky  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

1611741:vr  
041405



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/506,414	FIRST NAMED APPLICANT Gene Hung	ATTY. DOCKET NO. HOUSEE1.006NP
---	------------------------------------	-----------------------------------

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/US03/06314

LA. FILING DATE 03/03/2003	PRIORITY DATE 03/01/2002
-------------------------------	-----------------------------

20995  
KNOBBE MARTENS OLSON & BEAR LLP  
2040 MAIN STREET  
FOURTEENTH FLOOR  
IRVINE, CA 92614

CONFIRMATION NO. 8360

371 FORMALITIES LETTER



\*OC000000015193293\*

Date Mailed: 02/16/2005

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
  - APPLICANT MUST PROVIDE:
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
    - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

KAREN M WILLIAMS

Telephone: (703) 308-9140 EXT 213

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/506,414	PCT/US03/06314	HOUSEEI.006NP

FORM PCT/DO/EO/922 (371 Formalities Notice)